Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169870 | 0.97 | LTA4H (0.47) | LTA4HKCNH2CYSLTR2CYSLTR1EPHX2 | |
| SCHEMBL4998727 | 0.87 | LTA4H (0.49) | LTA4HKCNH2EPHX2 | |
| SCHEMBL2169432 | 0.85 | LTA4H (0.48) | LTA4HKCNH2CYSLTR2CYSLTR1 | |
| SCHEMBL4998620 | 0.85 | LTA4H (0.47) | LTA4HKCNH2EPHX2 | |
| SCHEMBL4692436 | 0.82 | LTA4H (0.49) | LTA4HKCNH2EPHX2 | |
| SCHEMBL4996090 | 0.81 | LTA4H (0.44) | LTA4HKCNH2CYSLTR2CYSLTR1EPHX2 | |
| SCHEMBL2171303 | 0.80 | LTA4H (0.56) | LTA4HKCNH2EPHX2 | |
| SCHEMBL4693392 | 0.80 | LTA4H (0.53) | LTA4HKCNH2EPHX2 | |
| SCHEMBL2169656 | 0.79 | LTA4H (0.53) | LTA4HKCNH2EPHX2 | |
| SCHEMBL2169428 | 0.79 | LTA4H (0.45) | LTA4HKCNH2CYSLTR2CYSLTR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KCNH2 2161/4885CYSLTR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.